Merck Oncology Strategy: With First-Line Lung Data, A New Day Dawns For Keytruda

27 Jun 2016
News

Jessica Merrill @Jessicaemerrill Jessica.merrill@informa.com

Executive Summary

Merck claims to have the broadest clinical development program for an anti-PD-1/L1 drug, with more than 270 trials under way testing Keytruda in 30 tumor types and 100 combinations.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Related Companies

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical Clinical Trials Innovation

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS057741

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS057741

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Merck Oncology Strategy: With First-Line Lung Data, A New Day Dawns For Keytruda

News

Executive Summary

Related Content

Opdivo's Failure In First-Line Lung Cancer Prompts Rethink On Trial Endpoints

Topics

Related Companies

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert